Large B-Cell Lymphoma (LBCL) research hub
3 indexed studies · 1 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy
This study is testing a new way to prepare people with a type of lymphoma (LBCL) for a special cell therapy called ALLO-501A. It compares two methods of preparing the body to see which works best and is safest.
Belgium · Germany · Austria - recruitingPHASE2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This study is testing a new medicine called Surovatamig for adults with certain types of B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It aims to see how well it works and if it's safe.
United States · Australia · Brazil - ongoing, recruitingTherapeutic exploratory (Phase II)
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
This study is testing a new cell therapy called ALLO-501A, along with another drug called ALLO-647, for adults with a type of blood cancer called Large B-Cell Lymphoma, where previous treatments haven't worked. It aims to see how safe and effective these new treatments are.
Italy · Spain